Physician profile
Amparo E Halecki
NPI 1386088144
$2,469.74
in general payments reported to CMS, 2019-2025
21 companies · $620 in 2025
The $620 reported for 2025 was more than what 77% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $199 · 2022: $420 · 2023: $417 · 2024: $813 · 2025: $620.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,762 · Education: $89.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,761.67 |
| Education | $89.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $306.56 | 2024-2025 | Uptravi, Opsumit, Opsynvi |
| Pfizer INC. | $301.44 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $256.63 | 2021-2025 | Farxiga |
| Janssen Pharmaceuticals, INC | $234.75 | 2022-2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $199.26 | 2021-2023 | Lifevest |
| Boston Scientific Corporation | $182.77 | 2023-2025 | Watchman Flx |
| Novo Nordisk INC | $156.98 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| E.R. Squibb & Sons, L.L.C. | $134.39 | 2022-2024 | Eliquis, Camzyos |
| Daiichi Sankyo INC. | $128.97 | 2023-2025 | Injectafer |
| Amgen INC. | $127.38 | 2023-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $125.81 | 2021-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $80.01 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $48.14 | 2021-2024 | Verquvo |
| Abbvie INC. | $46.74 | 2022 | |
| Kiniksa Pharmaceuticals, LTD. | $34.16 | 2023 | Arcalyst |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $33.78 | 2022 | |
| Abiomed | $19.17 | 2025 | |
| Kiniksa Pharmaceuticals International, Plc | $15.24 | 2024 | Arcalyst |
| Amarin Pharma, INC. | $13.24 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $12.60 | 2022 | |
| G Medical Diagnostic Services, INC. | $11.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amparo Halecki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.